VIDA Launches Cloud-Based Case Viewer to Improve Clinical Trial Imaging Workflows

May 24 00:30 2023
Case Viewer is the Latest Enhancement to VIDA’s Trial Imaging Management Platform.

WASHINGTON, D.C. – May 23, 2023 – VIDA Diagnostics, Inc. (VIDA), the leader in clinical imaging intelligence, today released a cloud-based case viewer, designed to enhance clinical trial imaging workflows. Users of the VIDA Intelligence Platform can now view clinical trial imaging cases directly in a web browser to review imaging and clinical data quickly and easily. This new capability will streamline quality-controlled data curation as cases and reader impressions are added to the digital biobank. The VIDA Intelligence Platform and case viewer application will be showcased at the American Thoracic Society (ATS) Annual Conference in both #1414 from May 21-24, 2023, in Washington, DC.

VIDA is leveraging its deep expertise in advanced imaging to deliver an integrated viewing solution that allows users to both increase efficiency and improve scan data quality. Historically, clinical trial imaging team members would need to run a separate desktop application to view clinical trial scans creating a disconnect among the trial imaging platform, the electronic Case Report Forms (eCRF), and the desktop viewer application. With VIDA’s integrated case viewer, these functions are all accessible centrally with the full case context from one cloud-based application, enhancing efficiency and reducing the possibility of errors.

“We’re committed to making it easy for sites to participate in imaging-based clinical trials,” said Susan Wood, PhD, CEO of VIDA. “The integration of our cloud case viewer into the platform will have a big impact in both efficiency and quality control, helping us deliver on our mission to accelerate the approval and adoption of life-saving therapies to patients.”

The case viewer will have an immediate impact on several clinical trial imaging workflows, including:

  • Quality control: Members of a trial team will now have immediate access to view the images collected, incorporating a visual quality control step into the workflow to ensure only high-quality data is added to the digital biobank.
  • Eligibility reads: Radiologists can quickly view images and assess patients’ imaging data for clinical trial eligibility. Eligibility results are made available to trial team members in real-time – all within the trial imaging management platform.


About VIDA Diagnostics, Inc.

VIDA is a clinical imaging intelligence company that is accelerating the development of life-saving therapies to patients through an AI-powered digital biomarker solution. With proprietary imaging biomarkers for precise quantitative endpoints and a trial imaging management solution, the VIDA Intelligence Platform is helping biopharma sponsors save millions in drug development costs. VIDA’s software is FDA cleared, CE-marked, Health Canada licensed, TGA registered, and PMDA certified for clinical use in the U.S., European Economic Area, Canada, Australia, and Japan.

Learn more at https://vidalung.ai. Follow @vidalung on Twitter and LinkedIn.

Media Contact
Company Name: VIDA
Contact Person: Sara Ceder
Email: Send Email
City: Edina
State: Minnesota
Country: United States
Website: www.vidalung.ai

view more articles

About Article Author